Inovio and The Wistar Institute receive more than $4.6 million in R&D funding to advance vaccines against TB & malaria

PLYMOUTH MEETING, Pa., Feb. 12, 2018 -- Inovio Pharmaceuticals, Inc. today announced that the company is collaborating with The Wistar Institute to advance two novel SynCon^® vaccine programs against tuberculosis (TB) and malaria, fully funded by more than $4.6 million in total grants from the Bill & Melinda Gates Foundation and the National Institutes of Health (NIH).